NU 578
Unit 1–5 Exam
(2026/2027) (PDF) | Advanced Nursing | University of South Alabama
| Verified Questions and Answers with Rationales | Complete Study
Guide
THIS EXAM INCLUDES:
✔️ 100% Solved Questions and Answers
✔️ Verified Answers with Detailed Rationales
✔️ Graduate-Level Exam Preparation
✔️ High-Yield Practice Questions
✔️ Structured for Quick Review and Knowledge Reinforcement
✔️ Ideal for Quizzes, Midterms, and Comprehensive Exams
✔️ Suitable for MSN, NP, and Advanced Practice Nursing Students
✔️ Printable PDF Format
,Unit Primary Focus Areas Question Range
Pharmacokinetics, Pharmacodynamics,
#1–10, 46–50
Unit CYP450, Drug Metabolism,
71–75, 141–
1 Pharmacogenomics, Ion Trapping,
144
Bioavailability, Renal Dosing, Herbals
ANS Pharmacology, Antibiotics,
#11–20, 51–5
Unit Antifungals, Antivirals (Influenza, HSV),
76–84, 139–
2 Antiparasitics, TB Drugs, C. difficile,
140
Gonorrhea, HIV basics, Vaccines
Cardiovascular (HF, HTN, Arrhythmias,
#21–28, 56–6
Unit Anticoagulants, Antiplatelets), Renal
85–92, 149–
3 (Diuretics, CKD), Lipids, Diabetic renal
152
considerations
Endocrine (DM, Thyroid, Osteoporosis,
Gout), Respiratory (Asthma, COPD), #29–35, 61–6
Immunologic (Biologics, 93–100, 111–
Unit
Immunosuppressants, MS), Psychiatric 120, 126–135
4
(Antidepressants, Antipsychotics, Mood 153–159, 166
Stabilizers, AEDs), Pain Management, 170
Reproductive, GI, Geriatric/Pediatric
Anti-infectives (HIV, HCV, TB, Malaria),
#36–45, 66–7
Chemotherapy (CINV, Myelosuppression,
101–110, 121
Unit Ototoxicity, Cardiotoxicity, Antidotes),
125, 136–138
5 Immunosuppressants (Transplant),
145–148, 160
Oncologic Supportive Care, Clinical
165
Decision-Making, Toxicology
,NU 578 Units 1–5 Exam
UNIT 1:
Question 1
A patient with severe liver cirrhosis is prescribed a medication that
undergoes extensive first-pass metabolism. The prescriber should
anticipate which of the following?
A. Decreased oral bioavailability
B. Increased oral bioavailability
C. No change in bioavailability
D. Increased renal excretion
Answer: B
Rationale: First-pass metabolism occurs in the liver. In patients with severe
liver disease, hepatic extraction is reduced, allowing more of the drug to
reach systemic circulation. This results in increased oral bioavailability.
Providers must anticipate the need for dose reduction to prevent toxicity.
Renal excretion (D) is not directly affected by first-pass metabolism.
Decreased oral bioavailability (A) would occur with enhanced metabolism,
not liver disease.
, Question 2
A drug has a volume of distribution (Vd) of 0.2 L/kg. This suggests the drug
is primarily:
A. Confined to plasma
B. Distributed into total body water
C. Accumulated in fat tissue
D. Bound extensively to tissues
Answer: A
Rationale: A Vd of 0.05–0.2 L/kg indicates the drug remains primarily in
the plasma compartment. Total body water Vd is approximately 0.5 L/kg.
High tissue binding would increase Vd significantly. Lipid-soluble drugs
that accumulate in fat have much larger Vd values (e.g., >1 L/kg).
Question 3
Which CYP450 enzyme is most commonly involved in clinically significant
drug-drug interactions?
A. CYP2D6
B. CYP3A4
C. CYP1A2
D. CYP2C9
Answer: B
Unit 1–5 Exam
(2026/2027) (PDF) | Advanced Nursing | University of South Alabama
| Verified Questions and Answers with Rationales | Complete Study
Guide
THIS EXAM INCLUDES:
✔️ 100% Solved Questions and Answers
✔️ Verified Answers with Detailed Rationales
✔️ Graduate-Level Exam Preparation
✔️ High-Yield Practice Questions
✔️ Structured for Quick Review and Knowledge Reinforcement
✔️ Ideal for Quizzes, Midterms, and Comprehensive Exams
✔️ Suitable for MSN, NP, and Advanced Practice Nursing Students
✔️ Printable PDF Format
,Unit Primary Focus Areas Question Range
Pharmacokinetics, Pharmacodynamics,
#1–10, 46–50
Unit CYP450, Drug Metabolism,
71–75, 141–
1 Pharmacogenomics, Ion Trapping,
144
Bioavailability, Renal Dosing, Herbals
ANS Pharmacology, Antibiotics,
#11–20, 51–5
Unit Antifungals, Antivirals (Influenza, HSV),
76–84, 139–
2 Antiparasitics, TB Drugs, C. difficile,
140
Gonorrhea, HIV basics, Vaccines
Cardiovascular (HF, HTN, Arrhythmias,
#21–28, 56–6
Unit Anticoagulants, Antiplatelets), Renal
85–92, 149–
3 (Diuretics, CKD), Lipids, Diabetic renal
152
considerations
Endocrine (DM, Thyroid, Osteoporosis,
Gout), Respiratory (Asthma, COPD), #29–35, 61–6
Immunologic (Biologics, 93–100, 111–
Unit
Immunosuppressants, MS), Psychiatric 120, 126–135
4
(Antidepressants, Antipsychotics, Mood 153–159, 166
Stabilizers, AEDs), Pain Management, 170
Reproductive, GI, Geriatric/Pediatric
Anti-infectives (HIV, HCV, TB, Malaria),
#36–45, 66–7
Chemotherapy (CINV, Myelosuppression,
101–110, 121
Unit Ototoxicity, Cardiotoxicity, Antidotes),
125, 136–138
5 Immunosuppressants (Transplant),
145–148, 160
Oncologic Supportive Care, Clinical
165
Decision-Making, Toxicology
,NU 578 Units 1–5 Exam
UNIT 1:
Question 1
A patient with severe liver cirrhosis is prescribed a medication that
undergoes extensive first-pass metabolism. The prescriber should
anticipate which of the following?
A. Decreased oral bioavailability
B. Increased oral bioavailability
C. No change in bioavailability
D. Increased renal excretion
Answer: B
Rationale: First-pass metabolism occurs in the liver. In patients with severe
liver disease, hepatic extraction is reduced, allowing more of the drug to
reach systemic circulation. This results in increased oral bioavailability.
Providers must anticipate the need for dose reduction to prevent toxicity.
Renal excretion (D) is not directly affected by first-pass metabolism.
Decreased oral bioavailability (A) would occur with enhanced metabolism,
not liver disease.
, Question 2
A drug has a volume of distribution (Vd) of 0.2 L/kg. This suggests the drug
is primarily:
A. Confined to plasma
B. Distributed into total body water
C. Accumulated in fat tissue
D. Bound extensively to tissues
Answer: A
Rationale: A Vd of 0.05–0.2 L/kg indicates the drug remains primarily in
the plasma compartment. Total body water Vd is approximately 0.5 L/kg.
High tissue binding would increase Vd significantly. Lipid-soluble drugs
that accumulate in fat have much larger Vd values (e.g., >1 L/kg).
Question 3
Which CYP450 enzyme is most commonly involved in clinically significant
drug-drug interactions?
A. CYP2D6
B. CYP3A4
C. CYP1A2
D. CYP2C9
Answer: B
